Italian study backs Matritech's bladder cancer test:
This article was originally published in Clinica
Executive Summary
Matritech's NMP22 urine test for bladder cancer is better at detecting the disease than traditional urine cytology or the bladder tumour antigen (BTA) test, according to an Italian study. Researchers at the Institute of Urology in Milan compared the three tests in 105 bladder cancer patients. They found that NMP22 levels showed a sensitivity of 92% for transitional cell carcinoma of the bladder compared with 46.6% for urinary cytology and 50.6% for the BTA test which is made by Polymedco of Cortlandt Manor, New York. The study is published in the February issue of European Urology.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.